1 research outputs found
DR-70 as a novel diagnostic biomarker for gastric cancer
Background/Aims: To assess the utility of the DR-70 immunoassay in the
diagnosis of gastric cancer.
Materials and Methods: A total of 29 patients with histologically proven
malignant gastric tumor and 29 healthy blood donors were enrolled in
this study. DR-70 immunoassay was performed using an enzyme-linked
immunosorbent assay kit to quantify the serum levels of fibrin
degradation products.
Results: The DR-70 values in patients with gastric cancer significantly
differed from the values in controls (p<0.0001). Receiver operating
characteristic curve analysis revealed >= 1.45 mu g/mL as the best
cut-off value to distinguish between patients with gastric cancer and
healthy controls. The area under the receiver operating characteristic
curve was 0.871. Using >= 1.45 mu g/mL as the cut-off value, the DR-70
immunoassay showed a good clinical performance with a sensitivity of
82.8\% and a specificity of 79.3\%. The positive predictive value was
80.0\%, and the negative predictive value was 82.1\%.
Conclusion: The DR-70 immunoassay reliably differs between gastric
cancer and healthy controls, promising to become a useful cancer
detection tool in clinical practice